

Ohio Board of Nursing www.nursing.ohio.gov

17 South High Street, Suite 400 • Columbus, Ohio 43215-7410 • (614) 466-3947

| | (Original New Drug Applications: FDA) | | | |
|--|---------------------------------------|--|---|--|
| Generic Name | Trade Name | Indication(s) | CPG Action/Date | |
| | | 2012 | | |
| Ivacaftor Formulary Pg. 10 | Kalydeco | <i>Endocrine & Metabolic</i> <i>Agents: Ivacaftor.</i> Indicated for the treatment of cystic fibrosis in patients 6 years and older who have a G551D mutation in the cystic fibrosis transmembrane conductance regulator gene. | 10/22/12 Physician Initiated/ Physician Consult | |
| Zolpidem Tartrate Formulary Pg. 18 | Intermezzo | Central Nervous System Agents: Sedatives and Hypnotics, Nonbarbiturate. Indicated for use as needed for the treatment of insomnia when middle of the night awakening is followed by difficulty returning to sleep. | 10/22/12 CTP holder may prescribe. | |
| Zolpidem Tartrate | Edluar | Central Nervous System Agents: Sedatives and Hypnotics, Nonbarbiturate. Indicated for the short- term treatment of insomnia characterized by difficulties in sleep initiation. | 10/22/12 CTP holder may prescribe. | |
| Formulary Pg. 18 Tafluprost Ophthalmic Formulary Pg. 26 | Zioptan | Ophthalmic Agents:Agents for Glaucoma.Indicated for reducingelevated intraocularpressure in patients withopen-angle glaucoma orocular hypertension. | 10/22/12 Physician Initiated/ Physician Consult | |
| | June | 2012 | | |
| Dehydrated Alcohol Injection | Dehydrated Alcohol | Central Nervous System Agents: Dehydrated Alcohol. Indicated for relief of intractable chronic pain | 10/22/12 CTP holder May NOT prescribe. | |

New Drugs October 2012

1

| | | in such conditions as | |
|----------------------|----------|---------------------------|----------------------|
| | | inoperable cancer and | |
| | | trigeminal neuralgia in | |
| | | patients for whom | |
| | | neurosurgical | |
| | | procedures are | |
| Formulary Pg. 20 | | contraindicated. | |
| Darunavir Ethanolate | Prezista | Anti-Infectives: | 10/22/12 |
| | | Systemic: Antiretroviral | Physician Initiated/ |
| | | Agents: Protease | Physician Consult |
| | | Inhibitors. | |
| | | Indicated for the | |
| | | treatment of HIV-1 | |
| Formulary Pg. 23 | | infection. | |
| | July | / 2012 | • |
| Peginesatide Acetate | Omontys | Hematological Agents: | 10/22/12 |
| Injection | - | Erythropoiesis- | CTP holder may |
| | | Stimulating Agents. | prescribe. |
| | | Indicated for the | - |
| | | treatment of anemia due | |
| | | to chronic kidney | |
| | | disease in adult patients | |
| Formulary Pg. 6 | | on dialysis. | |
| | Augu | ist 2012 | |
| Taliglucerase Alfa | Elelyso | Endocrine & Metabolic | 10/22/12 |
| - | | Agents: Taliglucerase | Physician Initiated/ |
| | | Alfa. | Physician Consult |
| | | Indicated for long-term | |
| | | enzyme replacement | |
| | | therapy for adults with a | |
| | | confirmed diagnosis of | |
| Formulary Pg. 9 | | type 1 Gaucher disease. | |
| Avanafil Oral | Strendra | Renal & Genitourinary | 10/22/12 |
| | | Agents: Impotence | CTP holder may |
| | | Agents. | prescribe. |
| | | Indicated for the | - |
| | | treatment of erectile | |
| Formulary Pg. 14 | | dysfunction. | |
| Rotigotine | Neupro | Central Nervous System | 10/22/12 |
| - | | Agents: Antiparkinson | CTP holder may |
| | | Agents: | prescribe. |
| | | Indicated for the | |
| | | treatment of the signs | |
| | | and symptoms of | |
| | | idiopathic Parkinson | |
| | | disease and for the | |
| | | treatment of moderate to | |
| | | severe primary restless | |
| | | legs syndrome. | |
| Formulary Pg. 20 | | | |
| 1 onnaiary 1 g. 20 | 1 | | |

| | Septer | nber 2012 | |
|---|-----------|---|--|
| Lucinactant Intratracheal Formulary Pg. 14 | Surfaxin | Respiratory Agents: Lung Surfactants. Indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk of RDS | Neonatal NP only may prescribe all others Physician Initiated/ Physician Consult. |
| Meningococcal Groups C and Y/ Haemophilus B Tetanus Toxoid Conjugagte Injection | Menhibrix | Biologic/ Immunologic Agents: Agents for Active Immunization. Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenza type b in children 6 weeks through 18 months of age. | 10/22/12 CTP holder may prescribe. |
| Pertuzumab | Perjeta | Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of metastatic breast cancer. | 10/22/12 CTP holder May NOT prescribe. |

New Drugs Indications/ Warnings October 2012 (New Drug Indications/ Black Box Warnings: FDA

| Generic Name | Trade Name | Indication(s) | CPG Action/Date |
|----------------------|----------------------|---|---|
| | Мау | 2012 | |
| None | | | |
| | June | 2012 | · |
| Streptomycin Sulfate | Streptomycin Sulfate | Anti-Infectives, Systemic: Aminoglycosides, Parenteral. New black box warning for risk of severe neurotoxic reactions in patients with impaired renal function or | Current: Physician Initiated/ Physician Consult 10/22/12 No Change. |
| Formulary Pg. 22 | | prerenal azotemia. | |
| Gentamicin Sulfate | Gentamicin Sulfate | Anti-Infectives, Systemic: Aminoglycosides, Parenteral. | Current: Physician Initiated/ Physician Consult |

| Farmelan Dr. 00 | | New black box warning | 10/22/12 No |
|----------------------------------|--------------------|--|--|
| Formulary Pg. 22 | | for risk of nephrotoxicity. | Change. |
| Tobramycin Injection | Tobramycin Sulfate | Anti-Infectives, Systemic: Aminoglycosides, Parenteral. | Current: Physician Initiated/ Physician Consult |
| | | New black box warning for causing potential | 10/22/12 No Change. |
| Formulary Pg. 22 | | ototoxicty and nephrotoxicity. | |
| Amikacin | Amikacin, Amikin | Anti-Infectives, | Current: |
| | | Systemic: Aminoglycosides, Parenteral. | Physician Initiated/ Physician Consult |
| Formulary Pg. 22 | | New black box warning for potential ototoxicity and nephrotoxicity associated with use. | 10/22/12 No Change. |
| Brentuximab Vedotin Injection | Adcetris | Antineoplastic Agents: Antibody-Drug Conjugates. New black box warning | Current: CTP holder may NOT prescribe. |
| Formulary Pg. 28 | | for risk of JC virus infection resulting in progressive multifocal leukoencephalopathy | 10/22/12 No Change. |
| r officiary r g. 20 | | (PML) and death. | |
| 1 | | 2012 | 1 |
| Sodium Nitrite | Sodium Nitrite | Endocrine & Metabolic Agents: Detoxification Agents: Antidotes. New black box warning for serious adverse reactions and death in humans from life- threatening hypotension and methemoglobin | Current: CTP holder may prescribe. 10/22/12 No Change. |
| Formulary Pg. 10 | | formulation. | |
| | Διιαυ | st 2012 | |
| Levofloxacin Oral | Levaquin | Anti-Infectives, Systemic: Fluoroquinolones. New indication for the treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis and | Current: CTP holder may prescribe. 10/22/12 No Change. |

| Formulary Pg. 21 | | adults and pediatric patients 6 months and older. | |
|------------------|--|---|--|
| September 2012 | | | |
| None | | | |

Formulary Revision Request October 2012

(Original New Drug Applications: FDA)

| Generic Name | Trade Name | Indication(s) | CPG Action/Date | | |
|------------------|--|--|---|--|--|
| Formula | Formulary Review Revision Request from Michelle Bolles, ACNP | | | | |
| Dexmedetomidine | Precedex | Central Nervous System Agents: Sedatives and Hypnotics, Nonbarbiturate. Indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care unit. | Current: CTP holder may NOT prescribe. 10/22/12 CTP holder may prescribe in institutional settings per institutional | | |
| Formulary Pg. 19 | | Requesting CTP holder may prescribe. | standards. | | |

Review of Prescribing Designations of PI/PC and CTP Holder May <u>NOT</u> Prescribe

Nutrients & Nutritional Agents (October 2012)

| Drug Category/ Drug Name | Indication(s): If reviewing a specific drug in a drug category | Current Prescribing Designation | CPG Action/Date |
|-----------------------------|---|---|--|
| | Vitamins, Minerals | s, Trace Elements | |
| Magnesium Sulfate IV | <i>Minerals.</i> Indicated for hypomagnesemia, prevention and control of convulsions of severe preeclampsia and eclampsia and for control of hypertension, encephalopathy and | Physician Initiated/ Physician Consult | 10/22/12 Physician Initiated/ Physician Consult for parenteral, but see Footnote 1 for NNP, ACNP, ACCNS CTP holders. |

| Formulary Pg, 5 | convulsions associated with acute nephritis in children. | | |
|--|--|--|--|
| Electrolytes Formulary Pg, 5 | Electrolytes. | Physician Initiated/ Physician Consult for parenteral, but see footnote 1 for NNP, ACNP, ACCNS CTP holders. | 10/22/12 Physician Initiated/ Physician Consult for parenteral, but see Footnote 1 for NNP, ACNP, ACCNS CTP holders. |
| Peritoneal Dialysis Solutions Formulary Pg, 5 | <i>Electrolytes: Peritoneal</i> <i>Dialysis Solutions.</i> Indicated for acute or chronic renal failure, acute poisoning by dialyzable toxins, intractable edema, hyperkalemia, hypercalcemia, azotemia and uremia. | Physician Initiated/ Physician Consult | 10/22/12 No Change. |
| Amino Acids Formulary Pg, 5 | Amino Acids. | PI/PC for parenteral. | 10/22/12 Physician Initiated/ Physician Consult for parenteral, but see Footnote 1 for NNP, ACNP, ACCNS CTP holders. |
| Enzymes Formulary Pg, 5 | Enzymes. | Physician Initiated/ Physician Consult for parenteral. | 10/22/12 No parenteral enzymes. This prescribing designation will be removed. |
| Intravenous Nutritional Therapy: protein substrates, caloric intake, lipids, vitamins, minerals, electrolytes, trace metals TPN | Intravenous Nutritional Therapy. | * see footnote 1 | 10/22/12 Physician Initiated/ Physician Consult for parenteral, but see Footnote 1 for NNP, ACNP, ACCNS CTP holders. |
| Formulary Pg, 5 Chelating Agents | Chelating Aconts | Physician Initiated/ | 10/22/12 No |
| Formulary Pg. 6 | Chelating Agents. | Physician Initiated/ Physician Consult | Change. |

| Trientene HCL | Chelating Agents. | Physician Initiated/ | 10/22/12 No |
|--------------------|-------------------------|----------------------|-------------|
| (Syprine) | Indicated for the | Physician Consult | Change. |
| | treatment of Wilson's | | - |
| | disease in patients who | | |
| | are intolerant of | | |
| Formulary Pg. 6 | penicillamine. | | |
| Succimer | Chelating Agents. | Physician Initiated/ | 10/22/12 No |
| (Chemet) | Indicated for treatment | Physician Consult | Change. |
| | of lead poisoning in | | |
| | children with blood | | |
| Formulary Pg. 6 | levels > 45 mcg/dl. | | |
| Dialysis Solutions | Dialysis Solutions: | Physician Initiated/ | 10/22/12 No |
| (Hemodialysis) | Hemodialysis. | Physician Consult | Change. |
| | | | |
| | | | |
| Formulary Pg. 6 | | | |